Remibrutinib
Brand names: Rhapsido · Active ingredient: Remibrutinib
In short: RHAPSIDO® is indicated for adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of: chronic spontaneous urticaria. symptomatic dermographism.
What is Remibrutinib used for?
RHAPSIDO® is indicated for adult patients who remain symptomatic despite use of H1 antihistamine for the treatment of:
chronic spontaneous urticaria.
symptomatic dermographism.
Remibrutinib dosage
The recommended dosage is 25 mg taken orally twice daily with or without food.
Swallow RHAPSIDO tablet whole with water. Do not split, crush, or chew RHAPSIDO.
Missed Dose(s)
If a dose or doses of RHAPSIDO is missed, skip the missed dose, and take the next dose at its regularly scheduled time. Do not take an extra dose(s) of RHAPSIDO to make up for a missed dose(s).
Interrupt treatment with RHAPSIDO for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding .
How to take Remibrutinib — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information).
Administration Instructions
Inform patients to take RHAPSIDO with or without food. Advise patients not to split, crush, or chew the tablet and to swallow the tablet whole with water .
Risk of Bleeding:
Inform patients that bleeding can occur with the use of RHAPSIDO, and to report any signs and symptoms to their healthcare practitioner. Inform patients that RHAPSIDO should be interrupted for 3 to 7 days for any surgical procedures. Instruct patients to inform their healthcare practitioner if they use RHAPSIDO with antithrombotic agents due to the potential increased risk of bleeding .
Live Attenuated Vaccines:
Instruct patients to inform the healthcare practitioner that they are taking RHAPSIDO prior to any potential vaccinations. Advise patients that the vaccines containing live virus (live and live-attenuated) should not be given during treatment with RHAPSIDO .
Pregnancy:
Advise patients that there is a pregnancy registry that monitors pregnancy outcomes in women exposed to RHAPSIDO during pregnancy . …
Warnings & precautions
Do not take this medicine if: None.
In clinical trials, mucocutaneous-related bleeding occurred in 9% of patients who received RHAPSIDO . Interrupt treatment with RHAPSIDO if bleeding is observed and resume if the benefit is expected to outweigh the risk.
Interrupt treatment with RHAPSIDO for 3 to 7 days pre- and post-surgery or invasive procedures .
Use of antithrombotic agents concomitantly with RHAPSIDO may further increase the risk of bleeding . Consider the benefits and risks of antithrombotic agents when used concomitantly with RHAPSIDO. Monitor for signs and symptoms of bleeding.
No data are available on the effects of live or live-attenuated vaccines in patients receiving RHAPSIDO. The use of live and live-attenuated vaccines should be avoided in patients receiving RHAPSIDO.
Remibrutinib side effects
Because clinical trials are conducted under widely varying conditions, adverse drug reaction (ADR) rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions in Adults with Chronic Spontaneous Urticaria (CSU)
The safety of RHAPSIDO was based on a pooled safety population from two identical clinical trials of 52 weeks duration, REMIX-1 and REMIX-2 . The pooled safety population consisted of 912 adult patients with CSU who remain symptomatic despite H1 antihistamine treatment and who received RHAPSIDO 25 mg orally twice daily (N=606) or placebo (N=306) for 24 weeks during the double-blind, controlled treatment period of the trial.
Adverse reactions that occurred at an incidence greater than or equal to 3% and more common than the placebo group from the pooled safety population (REMIX-1 and REMIX-2) during the 24-week blinded, placebo-controlled treatment period are shown in Table 1. …
Drug interactions
Strong or Moderate CYP3A4 Inhibitors
Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors.
Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure , which may increase the risk of RHAPSIDO adverse reactions.
Strong or Moderate CYP3A4 Inducers
Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers.
Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inducer decreases remibrutinib exposure , which may decrease the efficacy of RHAPSIDO.
P-gp Substrates
Monitor more frequently for adverse reactions when using RHAPSIDO with P-glycoprotein (P-gp) substrates where minimal concentration changes may lead to serious adverse reactions (e.g., digoxin).
Remibrutinib is a P-gp inhibitor. Remibrutinib increases exposure of P-gp substrates, which may increase the risk of adverse reactions related to P-gp substrates .
Antithrombotic Agents
Consider the risks and benefits of concomitant administration of antithrombotic agents with RHAPSIDO [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].
No data are available on concomitant use of RHAPSIDO with anticoagulants. …
About this medicine
RHAPSIDO (remibrutinib) is a kinase inhibitor.
Its empirical formula (remibrutinib) is C27H27F2N5O3. The chemical name for remibrutinib is N-(3-{6-Amino-5-[2-(N-methylprop-2-enamido)ethoxy]pyrimidin-4-yl}-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide. Its molecular weight is approximately 507.54 g/mol. The chemical structure of remibrutinib is:
Remibrutinib is white to pale yellow powder, and it is practically insoluble in water.
RHAPSIDO is supplied as film-coated tablets for oral administration, with each film-coated tablet containing 25 mg of remibrutinib. The tablet core inactive ingredients are copovidone, croscarmellose sodium, mannitol, microcrystalline cellulose, sodium lauryl sulfate, and sodium stearyl fumarate. The tablet coating inactive ingredients are polyethylene glycol 4000, polyvinyl alcohol, red iron oxide (E172), talc, titanium dioxide (E171), and yellow iron oxide (E172).
How it works: Remibrutinib is an oral, small molecule kinase inhibitor that inhibits Bruton’s tyrosine kinase (BTK). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e5e89bff-6ced-4165-acc5-fb13136b3a3d. Read the full official label on DailyMed.
Related medicines
Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Brimonidine Dupilumab